Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Successful treatment of NDM-type carbapenemase-producing CRKP bacteremia and intra-abdominal infection in severe acute pancreatitis with aztreonam-avibactam: a case report

Abstract

BackgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP), particularly NDM-type carbapenemase-producing isolates, remains a major therapeutic challenge in critically ill patients. Severe acute pancreatitis (SAP) may be complicated by intra-abdominal infection (IAI) and bloodstream infection (BSI), requiring timely antimicrobial susceptibility assessment to guide therapy.Case PresentationA 40-year-old male with SAP was admitted on hospital day 1 (D1) with respiratory and circulatory failure and multiple organ dysfunction. After initial stabilization, he developed recurrent fever with rising inflammatory markers. Blood and peripancreatic drainage fluid specimens obtained on D22 subsequently yielded CRKP with concordant susceptibility profiles. Phenotypic testing was suggestive of metallo-β-lactamase production and demonstrated marked in vitro activity of aztreonam-avibactam (ATM-AVI) (inhibition zone 32 mm; MIC <0.064 mg/L), whereas ceftazidime-avibactam (CZA) was inactive (MIC >16 mg/L). Based on these phenotypic susceptibility results, targeted ATM-AVI therapy (2 g plus 0.5 g IV every 6 h) was initiated on D27. Subsequent whole-genome sequencing identified a blaNDM-like carbapenemase gene with 99.3% sequence identity to blaNDM-1, providing mechanistic characterization of the resistance phenotype. Blood cultures on D34 and D39 were negative. Fever resolved, inflammatory markers decreased, and clinical improvement was observed without radiological progression. Therapeutic drug monitoring (TDM) confirmed adequate plasma exposure, and no clinically significant hepatic, renal, or hematologic abnormalities were observed.ConclusionThe favorable clinical and microbiological outcome occurred in the context of combined source control and phenotypic susceptibility-guided ATM-AVI therapy, with subsequent WGS providing mechanistic characterization of the resistance phenotype.

Related

  1. Detection of Carbapenemase-Producing Bacteria by Using an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method
    Anne Carricajo, Paul Verhoeven, Salim Guezzou +2
    Antimicrobial Agents and ChemotherapyPeer-reviewedLicence not statedFull text18 citedCell biologyMicrobiologyHAL
  2. Rapid inter-regional and cross-border dissemination of carbapenemase-producing Klebsiella pneumoniae ST6668, European Union, April 2022 to August 2026.
    Giulia Errico, Marius Linkevicius, Alessandra Lo Sciuto +33
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. Genomic characterization of IncC plasmid-mediated triple carbapenemase-producing Providencia hangzhouensis ST222.
    Odion O. Ikhimiukor, Catharine Prussing, Kailee Cummings +5
    Microbial genomicsPeer-reviewedCC BYFull textInfectious diseaseEurope PMCPMC
  4. Systematic surveillance of Carbapenemase-producing Enterobacterales reveals persistent spread of IMP-4 IncM2 plasmids in New Caledonia
    Alexandre Bourles, Léo Cousin, Gauthier Delvallez +14
    Communications MedicinePeer-reviewedCC BYFull textGeneral medicineDOAJ
  5. Prevention of carbapenemase-producing Enterobacterales outbreaks: evaluation of a simplified contact screening policy
    Jérémy Picard, Nicolas Galakhoff, Raoul Baron +8
    Infection Prevention in PracticePeer-reviewedCC BYFull textInfectious diseaseDOAJEurope PMCEurope PMCPMC
BibTeX
@article{wu2026successful,
  title = {{Successful treatment of NDM-type carbapenemase-producing CRKP bacteremia and intra-abdominal infection in severe acute pancreatitis with aztreonam-avibactam: a case report}},
  author = {Zhiyang Wu and Juan Zhang and Yingjie Wang and Xin Zhang and Zhi Li},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = nov,
  doi = {10.3389/fphar.2026.1910647},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1910647},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Successful treatment of NDM-type carbapenemase-producing CRKP bacteremia and intra-abdominal infection in severe acute pancreatitis with aztreonam-avibactam: a case report
AU  - Zhiyang Wu
AU  - Juan Zhang
AU  - Yingjie Wang
AU  - Xin Zhang
AU  - Zhi Li
PY  - 2026
DA  - 2026/11/12
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1910647
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1910647
AB  - BackgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP), particularly NDM-type carbapenemase-producing isolates, remains a major therapeutic challenge in critically ill patients. Severe acute pancreatitis (SAP) may be complicated by intra-abdominal infection (IAI) and bloodstream infection (BSI), requiring timely antimicrobial susceptibility assessment to guide therapy.Case PresentationA 40-year-old male with SAP was admitted on hospital day 1 (D1) with respiratory and circulatory failure and multiple organ dysfunction. After initial stabilization, he developed recurrent fever with rising inflammatory markers. Blood and peripancreatic drainage fluid specimens obtained on D22 subsequently yielded CRKP with concordant susceptibility profiles. Phenotypic testing was suggestive of metallo-β-lactamase production and demonstrated marked in vitro activity of aztreonam-avibactam (ATM-AVI) (inhibition zone 32 mm; MIC <0.064 mg/L), whereas ceftazidime-avibactam (CZA) was inactive (MIC >16 mg/L). Based on these phenotypic susceptibility results, targeted ATM-AVI therapy (2 g plus 0.5 g IV every 6 h) was initiated on D27. Subsequent whole-genome sequencing identified a blaNDM-like carbapenemase gene with 99.3% sequence identity to blaNDM-1, providing mechanistic characterization of the resistance phenotype. Blood cultures on D34 and D39 were negative. Fever resolved, inflammatory markers decreased, and clinical improvement was observed without radiological progression. Therapeutic drug monitoring (TDM) confirmed adequate plasma exposure, and no clinically significant hepatic, renal, or hematologic abnormalities were observed.ConclusionThe favorable clinical and microbiological outcome occurred in the context of combined source control and phenotypic susceptibility-guided ATM-AVI therapy, with subsequent WGS providing mechanistic characterization of the resistance phenotype.
SN  - 1663-9812
ER  -